EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Acquired Resistance to the PRMT5 Inhibitor Confers Collateral Sensitivity to MEK Inhibition in MTAP-Null Non-Small Cell Lung Cancer

Rongjie Fu, Yalong Wang iD, Ishita Rehman iD, Ella Bedford, Sana Sharif iD, Nghi D Nguyen iD, Reid T Powell, Andrew Adams, Weijun Liu iD, Shuyue Wang, Wei He, Yue Lu und 9 weitere

Biomolecules · 17.08.2026 · 16 (8) · 1198

DOI: 10.3390/biom16081198 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, online erschienen am 17.08.2026. Verfasst von Rongjie Fu und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA. Hauptthemen laut MEDLINE: Protein-Arginine N-Methyltransferases, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, Cancer Prevention and Research Institute of Texas, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Protein arginine methyltransferase 5 (PRMT5) is a synthetic lethal target in methylthioadenosine phosphorylase-deleted (MTAP-null) cancers. Second-generation methylthioadenosine (MTA)-cooperative PRMT5 inhibitors preferentially target MTAP-null cells while largely sparing MTAP-wildtype (MTAP-WT) cells, thereby improving tumor selectivity over first-generation PRMT5 inhibitors. Despite encouraging efficacy and safety signals in early clinical studies, the modest objective response rates (ORRs) observed with these inhibitors suggest that intrinsic or acquired resistance may limit their clinical benefit. Here, we investigated acquired resistance to the MTA-cooperative PRMT5 inhibitor BMS-986504/MRTX1719 in MTAP-null non-small cell lung cancer (NSCLC) cells and sought to identify therapeutic vulnerabilities that emerge upon resistance. Using multiple in vitro-derived resistant models, we found that acquired resistance was accompanied by cross-resistance to mechanistically distinct PRMT5 inhibitors. Notably, this phenotype was not fully explained by altered PRMT5 activity or changes in MTA levels. High-throughput drug screening of paired sensitive and resistant cells revealed increased sensitivity to MEK inhibitors following acquisition of MRTX1719 resistance in KRAS-wildtype NSCLC cells. Consistently, resistant cells exhibited rewired MAPK-related transcriptional programs. Together, these findings identify MEK inhibition as a reproducible collateral vulnerability associated with acquired MRTX1719 resistance in MTAP-null NSCLC models and support further evaluation of MEK inhibition as a potential treatment-switching strategy following resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein-Arginine N-MethyltransferasesCarcinoma, Non-Small-Cell LungLung NeoplasmsDrug Resistance, NeoplasmPurine-Nucleoside PhosphorylaseProtein Kinase InhibitorsHumansCell Line, Tumor

Stichwörter der Autor:innen

MAPK signalingMEK inhibitionMTA-cooperative PRMT5 inhibitorMTAP-nullPRMT5acquired resistance

Substanzen

Protein-Arginine N-MethyltransferasesPRMT5 protein, human5'-methylthioadenosine phosphorylasePurine-Nucleoside PhosphorylaseProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
  • Department of Biotechnology, The Neotia University, Sarisha 743368, West Bengal, India.
  • Department of Pharmacological and Pharmaceutical Sciences, The University of Houston College of Pharmacy, Houston, TX 77204, USA.
  • Texas A&M Health Center for Translational Cancer Research, Houston, TX 77030, USA.
  • Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Biology and Biochemistry, University of Houston, Houston, TX 77004, USA.

ORCID-Profile: Yalong Wang, Ishita Rehman, Sana Sharif, Nghi D Nguyen, Weijun Liu, Pooja Anil Shah, Taiping Chen, Clifford C Stephan, Xinli Liu, Han Xu

Förderung

  • NIH HHS
  • Cancer Prevention and Research Institute of Texas
  • NCI NIH HHS
  • American Cancer Society
  • United States Department of Defense
  • The University of Texas MD Anderson Cancer Center
  • NIGMS NIH HHS
  • CPRIT Core Facility Support Awards

Zitieren

APA

Fu, R., Wang, Y., Rehman, I., Bedford, E., Sharif, S., Nguyen, N. D., Powell, R. T., Adams, A., Liu, W., Wang, S., He, W., Lu, Y., Liu, B., Shah, P. A., Ahnert, J. R., Chen, T., Peng, W., Stephan, C. C., Liu, X., …, & Xu, H. (2026). Acquired Resistance to the PRMT5 Inhibitor Confers Collateral Sensitivity to MEK Inhibition in MTAP-Null Non-Small Cell Lung Cancer. Biomolecules, 16(8), 1198. https://doi.org/10.3390/biom16081198

Vancouver

Fu R, Wang Y, Rehman I, Bedford E, Sharif S, Nguyen ND, et al. Acquired Resistance to the PRMT5 Inhibitor Confers Collateral Sensitivity to MEK Inhibition in MTAP-Null Non-Small Cell Lung Cancer. Biomolecules. 2026;16(8):1198. doi:10.3390/biom16081198

BibTeX
@article{Fu2026,
  author = {Fu, Rongjie and Wang, Yalong and Rehman, Ishita and Bedford, Ella and Sharif, Sana and Nguyen, Nghi D and Powell, Reid T and Adams, Andrew and Liu, Weijun and Wang, Shuyue and He, Wei and Lu, Yue and Liu, Bin and Shah, Pooja Anil and Ahnert, Jordi Rodon and Chen, Taiping and Peng, Weiyi and Stephan, Clifford C and Liu, Xinli and Bedford, Mark T and Xu, Han},
  title = {Acquired Resistance to the PRMT5 Inhibitor Confers Collateral Sensitivity to MEK Inhibition in MTAP-Null Non-Small Cell Lung Cancer},
  journal = {Biomolecules},
  year = {2026},
  volume = {16},
  number = {8},
  pages = {1198},
  doi = {10.3390/biom16081198}
}
Kostenlos starten →